Are European laboratories ready to detect COVID-19?
A first assessment looking at the preparedness of EU/EEA laboratories to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demonstrates a fast implementation of molecular diagnostics by the European specialised laboratory networks. It also shows a good geographical coverage for testing.
In January 2020, a survey among laboratories to assess the capacity and quality for SARS-CoV-2 (previously 2019-nCoV) diagnostics as well as implementation barriers was conducted. The data provided by 47 laboratories in 30 EU/EEA countries were taken into account in a study released by Eurosurveillance.
The laboratories were asked to indicate their weekly capacity for molecular testing for SARS-CoV-2. Of the 47 participating laboratories, 38 indicated a capacity of minimum 8 275 tests per week.
At the time of the survey, an additional eight laboratories were in the process of implementing molecular diagnostics and these laboratories would, all combined, add a minimum capacity of 875 tests per week once this process would be complete.
Furthermore, the survey indicated a great willingness of laboratories to provide international diagnostic support and to share sequences to contribute to the monitoring of virus evolution and trace transmission chains.
The main challenges for test implementation were an initial lack of positive control, lack of personnel/time and a lack of primers and/or probes.
Read the full assessment
A first assessment looking at the preparedness of EU/EEA laboratories to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) demonstrates a fast implementation of molecular diagnostics by the European specialised laboratory networks. It also shows a good geographical coverage for testing.
Latest updates
Further reading
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 12-18 September, and includes updates on Ebola, malaria, botulism, avian influenza A(H9N2), influenza A(H5), respiratory virus epidemiology in the EU/.EEA, West Nile virus infections, chikungunya, dengue, Crimean-Congo haemorrhagic fever, Vibrio, measles, and expert deployments.
Communicable disease threats report, 12-18 September, week 38
English (3.41 MB - PDF)
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 29 August - 4 September, and includes updates on Ebola, SARS-CoV-2 variant classification, West Nile virus, Crimean-Congo haemorrhagic fever, dengue, chikungunya, vibrio, Middle East respiratory syndrome, malaria, influenza A (H9N2), and an overview of respiratory virus epidemiology in the EU/EEA.
Communicable disease threats report, 29 August - 4 September, week 36
English (4.84 MB - PDF)
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 22 - 28 August, and includes updates on diphtheria, Ebola, swine influenza A(H1N2), respiratory virus epidemiology, Crimean-Congo haemorrhagic fever, dengue, chikungunya virus disease, Vibrio growth, West Nile virus, cholera, poliovirus and expert deployments.
Communicable disease threats report, 22 - 28 August, week 35
English (3.94 MB - PDF)
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 15-21 August 2026, and includes updates on Ebola, respiratory virus epidemiology in the EU/EEA, swine flu, West Nile virus, Crimean-Congo haemorrhagic fever, dengue, chikungunya, vibrio, influenza, Dermatophilosis congolensis, Salmonella Enteritidis, and measles.
Communicable disease threats report, 15 - 21 August 2026, week 34
English (898.46 KB - PDF)
This report presents a description of COVID-19 vaccine coverage in the EU/EEA between 1 August 2025 and 27 March 2026, with some variation in reporting dates between countries.
COVID-19 vaccination coverage in the EU/EEA during the 2025–26 season campaigns
English (1.11 MB - PDF)